1. Home
  2. About Us
  3. News
  4. FDA Regulatory Considerations for Tobacco and Cannabis-Derived Substances

Healthcare and Life Sciences Hot Topics: FDA Regulatory Considerations for Tobacco and Cannabis-Derived Substances

Washington, D.C. partners discuss new developments and considerations for tobacco and cannabis-derived substance regulation.

August 15, 2019

Washington, D.C. partners Ben Haas and Elizabeth Richards examine the “stand alone” area of tobacco and the new regulations around vaporized tobacco. In addition, they discuss FDA’s views on cannabis-derived substances and recent guidance for how these substances will be regulated moving forward. 

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.